Grifols’ product portfolio just got a little larger with U.S. Food and Drug Administration approval of Xembify, a treatment for immune deficiency.
The medicine, a 20% immunoglobulin solution for subcutaneous -- or beneath the skin -- injection, treats Primary Humoral Immunodeficiency (PI) in patients 2 years old and older.
Grifols plans to launch Xembify in the United States in the fourth quarter of this year. The company also is laying the groundwork to sell the product in Canada, Europe and other global markets.
For more details, click
for the full story.